Statistics

Total Visits

Views
Switching to second-generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib-treated patients with chronic myeloid leukemia with more than 10% of BCR-ABL/ABL ratio at 3 months9

Select a period of time:

Number of views in the range

Views
Switching to second-generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib-treated patients with chronic myeloid leukemia with more than 10% of BCR-ABL/ABL ratio at 3 months4

Views

Views
November 20230
December 20230
January 20241
February 20241
March 20241
April 20240
May 20241
Download CSV file
 untranslated
 untranslated

Top country views

Views
United States4
 

Top cities views

Views
Ashburn1
Boardman1